CLINICAL TRIALS

Rifaximin for Hepatic Encephalopathy

Double-Blind, Randomized, Placebo Controlled Trial of Rifaximin for the Treatment of Hepatic Encephalopathy

IRB Number :

Trial Status :

Under IRB Review Phase: III

Why is this study being done?

Rifaximin is a non-absorbable oral antibiotic which may have potential efficacy for the treatment of hepatic encephalopathy. Treatment duration is 6 months. The use of lactulose will be allowed in the study. Positive results are anticipated to result in identifying efficacious therapy for patients with significant difficulties with recurrent and/or treatment-dependent hepatic encephalopathy.

Who is Eligible to Participate in the Study?

Patients with a diagnosis of cirrhosis and history of hepatic encephalopathy may be eligible.

Minimum Age:

18 years

Who can I Contact for Additional Information on this Trial?

Call Michelle Evjen at 507-266-0111 or Jayant A. Talwalkar, M.D.at 507-284-4823. Division of Gastroenterology & Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, 55905

What is/are the Locations of this Clinical Trial?

Rochester, MN; Scottsdale, AZ